Amy Schulman will join Elevance Health’s board as an independent director Jan. 12, 2026, according to a Dec. 10 news release.
She will serve on the audit and finance committees.
Ms. Schulman is currently a managing partner at the venture capital firm Polaris Partners, which oversees investments across healthcare and technology. She also chairs the board for Alnylam Pharmaceuticals and serves as a senior lecturer at Harvard Business School in Boston.
She has previously served in senior executive capacities at Pfizer — including executive vice president and general counsel — as well as president of Pfizer Nutrition.
At the Becker's 5th Annual Fall Payer Issues Roundtable, taking place November 2–3 in Chicago, payer executives and healthcare leaders will come together to discuss value-based care, regulatory changes, cost management strategies and innovations shaping the future of payer-provider collaboration. Apply for complimentary registration now.